Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156967 | 1.00 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1719719 | 1.00 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL7920805 | 0.94 | PPARG (0.55) | PPARGPPARA | |
| SCHEMBL1719565 | 0.92 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL1720449 | 0.92 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL7921154 | 0.91 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL4159916 | 0.91 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1720475 | 0.89 | PPARG (0.50) | PPARG | |
| SCHEMBL1720416 | 0.88 | PPARG (0.53) | PPARG | |
| SCHEMBL2217249 | 0.88 | PPARG (0.76) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022079-B2 | Methods of modulating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | disclosed |
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-22 | — | — | US | disclosed |
| US-7625914-B2 | Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| EP-1778624-B1 | TYROSINE DERIVATIVES AS PPAR-GAMMA-MODULATORS | SALVAT LAB SA (ES) | 2008-08-20 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| US-6274608-B1 | COMPOUNDS SUCH AS 5-(4-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTALEN-2-YL)-ETHOXY) -BENZYL)-THIAZOLIDINE-2,4-DI ONE USEFUL AS ANTIDIABETICS AND ANTI-OBESITY DRUGS | NOVO NORDISK A/S (DK) | 2001-08-14 | — | — | US | disclosed |
| EP-1083888-A1 | MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000063196-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-1999063983-A9 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999063983-A1 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | PPARG 1/4885PPARA 4/4885 |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885 |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.